$53.9999
0.2699[0.50%]
At close: Apr 26
$53.9999
0[0.00%]
After Hours: 6:47PM EDT
CRISPR Therapeutics
(NASDAQ:CRSP)CRISPR Therapeutics Stock (NASDAQ:CRSP), Analyst Ratings, Price Targets, Predictions
CRISPR Therapeutics AG has a consensus price target of $70.46, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from Citigroup, Needham, and Mizuho on April 18, 2024, April 11, 2024, and March 6, 2024. With an average price target of $92.67 between Citigroup, Needham, and Mizuho, there's an implied 71.61% upside for CRISPR Therapeutics AG from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
Needham
Mizuho
Morgan Stanley
RBC Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for CRISPR Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/18/2024 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | 64.82% | Citigroup | Yigal Nochomovitz | $88 → $89 | Maintains | Buy | Get Alert |
| 04/11/2024 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | 66.67% | Needham | Gil Blum | → $90 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | 83.33% | Mizuho | Salim Syed | $82 → $99 | Maintains | Buy | Get Alert |
| 02/26/2024 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | -11.11% | Morgan Stanley | Terence Flynn | $46 → $48 | Maintains | Underweight | Get Alert |
| 02/22/2024 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | 22.22% | RBC Capital | Luca Issi | $57 → $66 | Maintains | Sector Perform | Get Alert |
| 02/22/2024 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | 29.63% | Wells Fargo | Jim Birchenough | $55 → $70 | Maintains | Equal-Weight | Get Alert |
| 02/22/2024 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | 48.15% | Barclays | Gena Wang | $61 → $80 | Maintains | Equal-Weight | Get Alert |
| 02/22/2024 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | 107.41% | Chardan Capital | Geulah Livshits | $110 → $112 | Maintains | Buy | Get Alert |
| 02/21/2024 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | 66.67% | Needham | Gil Blum | $88 → $90 | Maintains | Buy | Get Alert |
| 02/15/2024 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | — | Wolfe Research | Andy Chen | — | Initiates | → Peer Perform | Get Alert |
| 12/11/2023 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | 5.56% | RBC Capital | Luca Issi | $50 → $57 | Maintains | Sector Perform | Get Alert |
| 12/11/2023 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | 196.3% | Truist Securities | Joon Lee | $220 → $160 | Maintains | Buy | Get Alert |
| 12/11/2023 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | 12.96% | Barclays | Gena Wang | $56 → $61 | Maintains | Equal-Weight | Get Alert |
| 12/11/2023 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | -44.44% | TD Cowen | Tyler Van Buren | → $30 | Downgrade | Market Perform → Underperform | Get Alert |
| 12/11/2023 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | 48.15% | JMP Securities | Silvan Tuerkcan | $74 → $80 | Maintains | Market Outperform | Get Alert |
| 12/11/2023 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | 62.96% | Needham | Gil Blum | $85 → $88 | Maintains | Buy | Get Alert |
| 12/08/2023 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | 307.41% | Truist Securities | Joon Lee | → $220 | Reiterates | Buy → Buy | Get Alert |
| 12/08/2023 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | 51.85% | Mizuho | Salim Syed | → $82 | Reiterates | Buy → Buy | Get Alert |
| 12/05/2023 | CRSP | Buy Now | CRISPR Therapeutics | $54.00 | 37.04% | JMP Securities | Silvan Tuerkcan | → $74 | Reiterates | Market Outperform → Market Outperform | Get Alert |
FAQ
What is the target price for CRISPR Therapeutics (CRSP)?
The latest price target for CRISPR Therapeutics (NASDAQ: CRSP) was reported by Citigroup on April 18, 2024. The analyst firm set a price target for $89.00 expecting CRSP to rise to within 12 months (a possible 64.82% upside). 47 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CRISPR Therapeutics (CRSP)?
The latest analyst rating for CRISPR Therapeutics (NASDAQ: CRSP) was provided by Citigroup, and CRISPR Therapeutics maintained their buy rating.
When was the last upgrade for CRISPR Therapeutics (CRSP)?
The last upgrade for CRISPR Therapeutics AG happened on August 18, 2023 when Citigroup raised their price target to $70. Citigroup previously had a neutral for CRISPR Therapeutics AG.
When was the last downgrade for CRISPR Therapeutics (CRSP)?
The last downgrade for CRISPR Therapeutics AG happened on December 11, 2023 when TD Cowen changed their price target from N/A to $30 for CRISPR Therapeutics AG.
When is the next analyst rating going to be posted or updated for CRISPR Therapeutics (CRSP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CRISPR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CRISPR Therapeutics was filed on April 18, 2024 so you should expect the next rating to be made available sometime around April 18, 2025.
Is the Analyst Rating CRISPR Therapeutics (CRSP) correct?
While ratings are subjective and will change, the latest CRISPR Therapeutics (CRSP) rating was a maintained with a price target of $88.00 to $89.00. The current price CRISPR Therapeutics (CRSP) is trading at is $54.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.